As of March 31, 2026, the Company held $379.8 million in cash, cash equivalents and marketable securities, which the Company expects to fund operations into 2028.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics, Inc. (TNGX) Q1 Earnings Cheat Sheet
- Tango Therapeutics Finalizes Separation Agreement with Former CFO
- Tango Therapeutics price target raised to $40 from $24 at Stifel
- Tango Therapeutics Overhauls Finance Leadership Amid Clinical Push
- Canaccord starts Tango Therapeutics with Buy on PRMT5 inhibitor